Sakditad Saowapa, Resident Physician at Texas Tech University Health Sciences Center, shared a post on LinkedIn:
“Excited to share my abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, published in Journal of Clinical Oncology
Studied AF patients on blood thinners with HCC
• Compared 1,087 AF+HCC vs. 13,087 AF-only patients
• HCC increased risks: Death (HR 1.72, 95% CI 1.36–2.17), Clots (HR 1.56–1.90), Bleeding (HR 1.36)
• Calls for tailored anticoagulation strategies
• Takeaway: Extra care for these patients to avoid big ouchies!”
Title: Risk of death, thrombotic, and hemorrhagic events in anticoagulated patients with atrial fibrillation and hepatocellular carcinoma: An analysis from a global federated dataset.
Authors: Sakditad Saowapa, Natchaya Polpichai, Shu-Yen Chan, Chalothorn Wannaphut, Manasawee Tanariyakul, Hector J Garcia Pleitez, Diego Olavarria Bernal, Chanakarn Kanitthamniyom, Pojsakorn Danpanichkul, Andrea Ortiz Maldonado, Chanokporn Puchongmart, Ben Thiravetyan, Panat Yanpiset, Rawipan Uaratanawong, Lukman Aderoju Tijani
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
